VRBPAC VOTING QUESTION # 1



Are the available data adequate to support the safety of ABRYSVO (RSVPreF) when administered to individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV?

Please vote "Yes" or "No"

VRBPAC VOTING QUESTION # 2



Are the available data adequate to support the effectiveness of ABRYSVO (RSVPreF) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older?

Please vote "Yes" or "No"